CAR T cells for CD19+ aggressive lymphoma
Part of Cancer clinical trials.
This trial tests a personalized treatment where your own immune cells are modified to find and kill lymphoma cells that have a protein called CD19. It may be an option if your lymphoma has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma must be an aggressive type that has come back or not responded to at least one standard chemotherapy and one other treatment.
- You must be over 18 and under 75 years old.
- Your lymphoma cells must have the CD19 protein (this is checked on a biopsy).
- You must not be pregnant or planning to become pregnant, and must use effective birth control during and for 3 months after treatment.
- You cannot have active hepatitis B or C, HIV, or serious organ problems like severe lung, heart, kidney, or liver disease.
- You cannot have active brain or central nervous system involvement from lymphoma (unless it has been successfully treated before starting the trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
Hear when a new Non-Hodgkin Lymphoma Refractory/ Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.